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Purpose: Atherosclerotic disease (AD) is the leading cause of death worldwide and in Saudi 
Arabia. Intensive risk reduction therapy plays a major role in reducing adverse cardiovascular 
outcomes in patients with AD. The level of awareness of this important fact amongst physi-
cians (family physicians, general internists, cardiologists and vascular surgeons) in managing 
these patients in Saudi Arabia is not currently known. This study was conducted to examine the 
perceptions and knowledge of risk reduction therapy in patients with AD amongst physicians 
in Saudi Arabia in two clinical presentations; coronary artery disease (CAD) and peripheral 
artery disease (PAD).
Materials and methods: We conducted a cross-sectional self-administered survey of 
897 physicians at different hospitals in four provinces in Saudi Arabia.
Results: The recommended targets of low density lipoprotein-cholesterol (LDL-C), blood 
  glucose, and blood pressure in patients with CAD and PAD were known as 40% and 36%; 
70% and 66%; and 32% and 28% of physicians, respectively. The initiation of antiplatelet 
medications, angiotensin converting enzyme (ACE) inhibitors, statins, and nicotine replace-
ment therapy for smokers in patients with CAD and PAD were recommended by 98% and 
97%; 52% and 34%; 61% and 56%; and 50% and 43% of physicians, respectively. Compared 
to other specialties, cardiologists had the lowest threshold for initiating risk reduction therapy, 
whereas vascular surgeons had the highest threshold.
Conclusion: The level of physician awareness of atherosclerosis risk reduction therapy across 
Saudi Arabia has revealed knowledge and action gaps. A call to action to implement effective 
strategies to encourage health professionals to use risk reduction therapy and increase public 
awareness is needed.
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Introduction
Atherosclerotic disease (AD) is a systemic disease that affects all arterial beds and 
can present with multiple clinical manifestations according to the end organ supplied, 
including the heart in coronary artery disease (CAD), and the lower extremities in 
peripheral artery disease (PAD). Risk factors for AD include male sex, advanced age, 
cigarette smoking, hypertension, diabetes, and hyperlipidaemia.1
Atherosclerotic disease is the leading cause of death worldwide and in 
Saudi Arabia.2,3 In Saudi Arabia, both CAD and PAD are a major public health 
problem, with an overall prevalence of 5.5%4 and 11.7% amongst people aged 
45 years and older,5 respectively. PAD is a marker of advanced atherosclerosis and 
is associated with an elevated risk of cardiovascular mortality and morbidity; with a 
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four-fold increased risk of myocardial infarction6 and a two 
to three-fold increased risk of stroke.7 Furthermore, the risk 
of cardiovascular mortality and morbidity in patients with 
PAD is comparable to that in patients with CAD.8
Reducing the adverse cardiovascular outcomes of athero-
sclerosis through risk factor identification and modification 
has been an active area of research over the past few decades. 
As a result, several large scale randomized clinical trials9–11 
and observational studies12,13 have shown intensive risk 
reduction therapy to be very effective and critical in reducing 
adverse cardiovascular outcomes in patients with AD, with 
many expert international committees recommending the 
use of risk reduction practices as summarized in Table 1.14–17 
However, the level of awareness of this information and the 
implementation of risk factor reduction therapy amongst 
all physicians is felt to be low, and has been shown to be 
suboptimal amongst general practitioners, internal medicine 
specialists, cardiologists, and vascular surgeons in the United 
States, Canada, and Europe.18–24
A small pilot study carried out at a university hospital in 
Saudi Arabia25 showed that there is a knowledge and action 
gap among physicians with respect to risk factor modification 
in patients with PAD. However, the knowledge and attitudes 
of physicians across Saudi Arabia towards risk reduction 
therapy for patients with AD are not known. Therefore, 
this study was performed to assess the knowledge of the 
  recommended target levels for blood pressure, blood glucose, 
and low density lipoprotein-cholesterol (LDL-C), as well as 
to explore physicians’ knowledge and attitudes towards risk 
reduction therapy in patients with AD. We also examined 
differences among physicians in the management of these 
factors in patients with PAD compared to patients with CAD 
in Saudi Arabia.
Materials and methods
A self-administered questionnaire was mailed to all family 
physicians, general internists, cardiologists, and vascular 
surgeons working at different hospitals in four provinces in 
Saudi Arabia: central – Riyadh and Qassim; east – Dammam, 
Khobar, Qatif, Jubail, Hafof, and Hafer Albatin; west – 
  Jeddah, Makkah, and Madinah; and south – Abha, Jizan, and 
Najran. The hospitals were randomly selected and included 
public, teaching, and private hospitals between March 1, 
2009 and February 28, 2010. The questionnaire was based 
on a previously published and validated questionnaire.25 
The questionnaire was anonymous and physicians provided 
consent prior to participation. This study was approved by 
the King Khalid University Hospital ethics review board, 
Riyadh, Saudi Arabia.
The survey consisted of multiple choice questions. 
Participant demographic information was collected, 
including age, sex, specialty, board certification status, and 
Table 1 Current recommendations of the American Heart Association and American College of Cardiology for risk reduction in 
patients with coronary artery disease compared to patients with peripheral arterial disease14,16,17
Recommendation Class of recommendation Level of evidence
CAD PAD CAD PAD
Medications used
  Antiplatelet All patients 1 1 A A
  Statin All patients 1 1 B B
  ACE inhibitors Symptomatic patients 
Asymptomatic patients
1 1 A B
2a 2a B B
Goals in managing
  Blood pressure Systolic 
  ,140 mmHg in all patients 
  ,130 mmHg in diabetic patients 
Diastolic 
  ,90 mmHg in all patients 
  ,80 mmHg in diabetic patients
 
1
 
1
 
A
 
A
LDL-C LDL , 2.5 mmol/L in all patients 1 1 A A
Diabetes HbA1c , 7% in diabetic patients 1 1 B B
Smoking Complete cessation in all patients 1 1 B B
BMI 18.5–24.9 kg/m2 in all patients 1 1 B B
Notes: Class 1: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is beneficial, useful, and effective; Class 2: Conditions 
for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment; Class 2a: Weight of evidence/opinion is 
in favor of usefulness/efficacy. level of evidence A: data derived from multiple randomized clinical trials or meta-analyses; level of evidence B: data derived from a single 
randomized trial or non-randomized studies.
Abbreviations:  AHA/ACC,  American  Heart  Association  and  American  College  of  Cardiology;  CAD,  coronary  artery  disease;  PAD,  peripheral  artery  disease; 
ACe, Angiotensin converting enzyme; lDl-C, low density lipoprotein-cholesterol; HbA1c, glycosylated hemoglobin A1c; BMi, body mass index.
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years of experience. All questions were asked with regards 
to patients with PAD and CAD. The questions aimed to: 
(1) assess participant knowledge of AD risk factors, including 
target levels of blood pressure, LDL-C, and blood glucose; 
and (2) assess participant attitudes towards AD risk reduc-
tion therapies. Participants were asked about their attitudes 
towards: patient counseling of cardiovascular risk reduction; 
comfort with recommending and instituting risk reduction 
therapy (smoking cessation, antiplatelet medications, statins, 
angiotensin converting enzyme [ACE] inhibitors, and anti-
hypertensive medications); factors that influence adequate 
risk reduction therapy delivery; proportion of patients with 
PAD or CAD who have their vascular risk factors evaluated 
systematically; and self-assessment of PAD or CAD risk 
reduction knowledge.
All survey results were expressed as percentages. The 
number of respondents who completed each question was 
used as the denominator for proportions of responses. The 
prespecified subgroups for comparison analysis of responses 
to PAD or CAD scenarios were by specialty type – family 
physicians, general internists, cardiologists, and vascular 
surgeons. Chi-square tests were used to compare propor-
tions between different subgroups. All P-values reported 
were two-tailed, and values of P = 0.05 were considered 
significant.
Results
529 of the 897 surveyed physicians completed the survey, rep-
resenting a response rate of 59%. Family physicians, general 
internists, cardiologists, and vascular surgeons represented 
20.2%, 41.4%, 28%, and 10.4% of the surveyed physicians, 
respectively. The results are depicted in Tables 2–5.
Physicians’ characteristics
Two-thirds of participating physicians were board-certified 
in their specialties and had been practicing for more 
than 10 years. Most of the respondents were working in 
nonacademic institutions (Table 2).
Physicians’ knowledge and attitude
The knowledge of the surveyed participants about the recom-
mended targets of LDL-C, blood pressure, and blood glucose 
was low for both CAD and PAD, and there was no statisti-
cal difference between the knowledge for both entities by 
specialty (Table 3). Only 38% knew that an ACE inhibitor 
can be initiated as an anti-atherosclerotic therapy in PAD 
patients irrespective of blood pressure status, compared to 
46% for CAD (P , 0.05). Although surveyed cardiologists 
still showed a knowledge gap in the use of ACE inhibitors 
for patients with AD, their positive response was statisti-
cally higher compared with other specialties (P , 0.05). 
The majority of surveyed physicians indicated that their 
self-assessment of risk reduction in PAD and CAD (78% 
and 77%, respectively) was average to above average. One-
third of surveyed family physicians indicated that their self-
assessment of risk reduction knowledge in CAD and PAD 
(31% and 30%, respectively) was below average.
Although surveyed physicians’ attitudes towards routine 
risk factor evaluation and associated patient counseling 
showed a very optimal response, the attitude towards patient 
assessment for risk factors was suboptimal (Table 4). Apart 
from routine initiation of antiplatelet therapy (98% for CAD 
and 96% for PAD), the attitude towards routine initiation and/
or modification of other risk reduction therapy was very poor, 
especially for the initiation of ACE inhibitors (52% for CAD 
and 34% for PAD). The surveyed cardiologists were observed 
to be more likely to initiate different risk reduction therapies 
when compared to other specialists (P , 0.05); however, on 
the whole, it was still suboptimal. On the other hand, vascular 
surgeons appeared to have the highest threshold for initiating 
these therapies; it was, however, only statistically significant 
for low rates of ACE inhibitor initiation (P , 0.05).
Table 2 Characteristics of physicians who completed the survey by specialty (N = 529)
Family physicians  
(N = 107)
General internists  
(N = 219)
Cardiologists  
(N = 148)
Vascular surgeons  
(N = 55)
All  
(N = 529)
Response rate, % 66 53 53 85 59
Mean age, y, ±SD 43.2 ± 5.2 39.7 ± 7.2 38.8 ± 6.5 39.5 ± 4.2 40.8 ± 5.3
Male sex, % 69 74 74 93 75
Board-certified, % 60 56 69 58 61
Academic institute, % 33 22 22 16 24
Years in practice
 , 5 years, % 19 12 8 17 13
  5–10 years, % 25 28 24 15 25
 . 10 years, % 56 60 68 68 62
Abbreviations: n, number; SD, standard deviation.
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Barriers to the delivery of risk  
reduction therapy
The barriers to the delivery of adequate risk reduction therapy 
are shown in Table 5.
Discussion
In this study we found that even though the majority of 
surveyed physicians evaluate and counsel patients with AD 
(CAD and PAD) for their risk factors, knowledge and action 
remain suboptimal, with clear gaps in knowledge identified. 
The majority of surveyed physicians rated their knowledge 
about risk reduction as average or above average. However, 
clear deficiencies in knowledge were identified including: 
(1) the recommended target levels for blood pressure, blood 
glucose, and LDL-C; and (2) that ACE inhibitor medications 
can be used in patients with atherosclerosis irrespective of 
blood pressure status to reduce atherosclerotic complications 
and cardiovascular death, with less than half of participants 
aware of this fact. Furthermore, initiation of all components 
of risk reduction therapy except antiplatelet medication 
was poor. The action gap was most prominent amongst 
family physicians and vascular surgeons when compared to 
other specialties.
Our findings could be explained by the absence of 
national or locally adapted guidelines in managing patients 
with AD, self-audit of practice, and focused continuing 
medical education programs on risk reduction therapy. 
Furthermore, suboptimal use of ACE inhibitors could be 
explained by the fact that the supporting evidence for the 
use of ACE inhibitors in patients with PAD to reduce the 
risk of adverse cardiovascular events is not Level A evi-
dence, and is also dependent on the presence of symptoms 
(ie, class 2a recommendation for symptomatic patients with 
PAD, and Class 2b recommendation for asymptomatic 
patients).14
Knowledge and action gaps in managing risk fac-
tors in patients with AD have also been shown amongst 
physicians in the United Kingdom, the United States, and 
Canada.18,22,23,26,27 Cassar et al22 showed that over a quarter 
of UK vascular surgeons did not screen for diabetes or 
measure blood pressure in patients with PAD. For instance, 
only 34% of vascular surgeons treated patients with claudi-
cation if cholesterol levels were greater than 5.5 mmol/L. 
  McDermott et al18 showed that only 45.5% of internal 
medicine physicians prescribe antiplatelet medications to 
patients with PAD compared with 52.5% of vascular sur-
geons, and only 16.8% of vascular surgeons were aware of 
the large effect of cholesterol lowering on the risk of future 
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cardiovascular events in patients with PAD compared to 
43.6% of the internal medicine physicians. Furthermore, 
even amongst cardiologists who were surveyed there were 
knowledge and action gaps in dealing with atherosclerotic 
risk. Al-Omran et al23 showed that utilization of risk reduc-
tion pharmacotherapy and knowledge of the recommended 
target levels of blood glucose, blood pressure, and LDL-C 
levels in patients with PAD amongst Canadian vascular 
surgeons was suboptimal. Mukherjee et al26 showed a sub-
optimal use of lifestyle modifications including: smoking 
cessation; exercise; weight reduction and diet for lipid 
control; and evidence-based therapy including antiplatelet 
medications, ACE-inhibitors, beta-blockers, and statins, 
in patients undergoing peripheral vascular interventions 
for PAD at hospital discharge and at 6 months follow-up. 
The knowledge and action gaps in managing risk factors in 
patients with AD from previously published studies18,22–23,27 
along with our data, support the fact that there is an inter-
national trend of suboptimal use of atherosclerotic risk 
reduction therapies.
In the evaluation of these results, certain limitations 
merit emphasis. The validated questionnaire used in this 
study was based on the 2006 recommendations for sec-
ondary prevention.16 An update of recommendations has 
been released in 2011;17 however, there were no major 
differences in the recommendations that were used in the 
questionnaire for surveyed physicians. As the data repre-
sented self-reported perceptions of knowledge, they may 
indicate an underestimation of the true knowledge gap 
that exists. Lastly, the survey form did not differentiate 
between symptomatic and asymptomatic atherosclerotic 
disease with regards to the use of ACE inhibitors as a risk 
reduction therapy.
Conclusion
In Saudi Arabia there are knowledge and action gaps with 
regards to AD risk reduction therapy amongst physicians, 
despite a considerable effort to evaluate and counsel patients 
for their risk factors. Given the heightened risk of cardiovas-
cular adverse outcomes in patients with AD, and the fact that 
AD is the leading cause of death in Saudi Arabia,3 the results 
of this study have important and immediate implications. 
This study may be used to support a call to action for AD 
management and provide guidance for targeted interventions 
including: locally adapted clinical practice guidelines, self-
audit of practice, continuing medical education programs, 
public awareness campaigns, the inclusion of risk reduction 
pharmacotherapy as a plenary topic at scientific meetings, 
and other educational outreach programs that aim to bring 
physicians’ practice into agreement with current guidelines 
for AD risk reduction.
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